LabTestSuperstore.
Range Atlas

AI-collected, not medically reviewed. Compare source context, not your health status.

Choose the units printed on your report.

Vitamin D 25-hydroxy: ranges and targets

7 sources / 10 ranges · ng/mL

Order test ↗

Categories and treatment goals are not interchangeable. Blank chart areas do not mean normal. Display values are rounded.

Shared scale (ng/mL)

104070

Clinical categories and treatment goals

Mayo Clinic Laboratories

Source category

United States · Any sex · adult

Mayo optimum range used as US unit tiebreaker

20 to 50 ng/mL

104070
Source details: Mayo Clinic Laboratories, Source category
Native values:
20 to 50 ng/mL
Context:
Mayo optimum range used as US unit tiebreaker
Population / collection / assay:
any; adult. Mayo optimum range used as US unit tiebreaker Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Mayo Clinic Laboratories (new tab)

KK Women and Children Hospital

Source category

Singapore · Any sex · adult

KKH classifies vitamin D deficiency below 12 ng/mL

Upper boundary 12 ng/mL

104070

Arrow: continues beyond the displayed scale.

Source details: KK Women and Children Hospital, Source category
Native values:
Upper boundary 12 ng/mL
Context:
KKH classifies vitamin D deficiency below 12 ng/mL
Population / collection / assay:
any; adult. KKH classifies vitamin D deficiency below 12 ng/mL Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read KK Women and Children Hospital (new tab)

Swiss Federal Commission for Nutrition report

Source category

Switzerland · Any sex · adult

Swiss report treats below 50 nmol/L as below adequate, so adequacy is at or above 20 ng/mL

Lower boundary 20 ng/mL

104070

Arrow: continues beyond the displayed scale.

Source details: Swiss Federal Commission for Nutrition report, Source category
Native values:
Lower boundary 50 nmol/L
Context:
Swiss report treats below 50 nmol/L as below adequate, so adequacy is at or above 20 ng/mL
Population / collection / assay:
any; adult. Swiss report treats below 50 nmol/L as below adequate, so adequacy is at or above 20 ng/mL Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Swiss Federal Commission for Nutrition report (new tab)

Oxford University Hospitals

Source category

United Kingdom · Any sex · adult

Oxford NHS page classifies 25 to 50 nmol/L as insufficiency

10 to 20 ng/mL

104070
Source details: Oxford University Hospitals, Source category
Native values:
25 to 50 nmol/L
Context:
Oxford NHS page classifies 25 to 50 nmol/L as insufficiency
Population / collection / assay:
any; adult. Oxford NHS page classifies 25 to 50 nmol/L as insufficiency Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Oxford University Hospitals (new tab)

RCPA Manual

Source category

Australia · Any sex · adult

RCPA says vitamin D adequacy is at least 50 nmol/L at end of winter

Lower boundary 20 ng/mL

104070

Arrow: continues beyond the displayed scale.

Source details: RCPA Manual, Source category
Native values:
Lower boundary 50 nmol/L
Context:
RCPA says vitamin D adequacy is at least 50 nmol/L at end of winter
Population / collection / assay:
any; adult. RCPA says vitamin D adequacy is at least 50 nmol/L at end of winter Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read RCPA Manual (new tab)

NIH Office of Dietary Supplements / 4 ranges

Deficiency-associated category

United States · Any sex · adult

Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone.

< 12 ng/mL

104070

Arrow: continues beyond the displayed scale.

Source details: NIH Office of Dietary Supplements, Deficiency-associated category
Native values:
< 12 ng/mL
Context:
NIH ODS summary of FNB/NASEM conclusions for healthy individuals. Adequacy and potential adverse-effect categories overlap; the adequacy floor is not an unbounded safe zone. Assay variation matters.
Population / collection / assay:
any; adult. Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone. Any additional details not recorded here remain unspecified.
Source date/version:
2025-06-27
Last verified in this pass:
2026-09-20. Recorded access: 2026-09-20.
Verification:
verified_numeric_source. Publisher-hosted text checked September 20, 2026. Not a medical review.
Locator:
Assessing vitamin D status, Table 1
Read NIH Office of Dietary Supplements (new tab)

Generally inadequate category

United States · Any sex · adult

Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone.

12 to < 20 ng/mL

104070
Source details: NIH Office of Dietary Supplements, Generally inadequate category
Native values:
12 to < 20 ng/mL
Context:
NIH ODS summary of FNB/NASEM conclusions for healthy individuals. Adequacy and potential adverse-effect categories overlap; the adequacy floor is not an unbounded safe zone. Assay variation matters.
Population / collection / assay:
any; adult. Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone. Any additional details not recorded here remain unspecified.
Source date/version:
2025-06-27
Last verified in this pass:
2026-09-20. Recorded access: 2026-09-20.
Verification:
verified_numeric_source. Publisher-hosted text checked September 20, 2026. Not a medical review.
Locator:
Assessing vitamin D status, Table 1
Read NIH Office of Dietary Supplements (new tab)

Generally adequate category

United States · Any sex · adult

Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone.

≥ 20 ng/mL

104070

Arrow: continues beyond the displayed scale.

Source details: NIH Office of Dietary Supplements, Generally adequate category
Native values:
≥ 20 ng/mL
Context:
NIH ODS summary of FNB/NASEM conclusions for healthy individuals. Adequacy and potential adverse-effect categories overlap; the adequacy floor is not an unbounded safe zone. Assay variation matters.
Population / collection / assay:
any; adult. Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone. Any additional details not recorded here remain unspecified.
Source date/version:
2025-06-27
Last verified in this pass:
2026-09-20. Recorded access: 2026-09-20.
Verification:
verified_numeric_source. Publisher-hosted text checked September 20, 2026. Not a medical review.
Locator:
Assessing vitamin D status, Table 1
Read NIH Office of Dietary Supplements (new tab)

Potential adverse effects

United States · Any sex · adult

Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone.

> 50 ng/mL

104070

Arrow: continues beyond the displayed scale.

Source details: NIH Office of Dietary Supplements, Potential adverse effects
Native values:
> 50 ng/mL
Context:
NIH ODS summary of FNB/NASEM conclusions for healthy individuals. Adequacy and potential adverse-effect categories overlap; the adequacy floor is not an unbounded safe zone. Assay variation matters.
Population / collection / assay:
any; adult. Healthy individuals; NIH ODS summary of FNB/NASEM. Categories overlap: adequacy is not an unbounded safe zone. Any additional details not recorded here remain unspecified.
Source date/version:
2025-06-27
Last verified in this pass:
2026-09-20. Recorded access: 2026-09-20.
Verification:
verified_numeric_source. Publisher-hosted text checked September 20, 2026. Not a medical review.
Locator:
Assessing vitamin D status, Table 1
Read NIH Office of Dietary Supplements (new tab)

Named clinician and other published views

Mark Hyman

Published view

Named view · Any sex · adult

Mark Hyman optimal vitamin D range

40 to 70 ng/mL

104070
Source details: Mark Hyman, Published view
Native values:
40 to 70 ng/mL
Context:
Mark Hyman optimal vitamin D range
Population / collection / assay:
any; adult. Mark Hyman optimal vitamin D range Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Mark Hyman (new tab)

25(OH)D uses the NIH ODS convention of 1 ng/mL = 2.5 nmol/L. Assay variation and source population still matter. Source comparison in common US units

2 source rows are withheld pending primary-source verification. Withheld numbers are not included in the chart or public dataset.

Methodology, units and limitations

AI-collected source-comparison prototype. Not medically reviewed. Not a diagnostic tool. Reference intervals describe a source population; categories and treatment goals have different purposes. Named views do not establish a universal optimum. Country identifies a source, not a biological normal for everyone there.

Source counts use stable publisher IDs; one source may supply several legitimate categories. Source dates and recorded access dates are separate. Older rows explicitly marked not rechecked have not received a new source review. Missing age, fasting, assay and risk details are not inferred.

Strict < and > differ from inclusive ≤ and ≥. Approximate and unknown boundaries are labeled, not converted into exact cutoffs. Printed endpoint precision is preserved; gaps between source categories are not silently filled.

Bars show only the visible portion of each interval. Arrows indicate continuation; small intervals are not enlarged to imply a wider range. Display rounding does not change stored values. Numerically equivalent units do not change the numbers.

Personal-result entry is not available in this release. Do not enter health results into the marker finder. The tool does not classify you, recommend treatment or adjust ranges for your age.